Indegene Share Price Target 2025, 2026, 2030, 2040, 2050

Indegene is a global healthcare technology company that helps medicine and medical-device companies to make new products, test them, follow all rules, and launch them in the market using easy digital tools, AI, and data. It provides support like digital marketing, data help, clinical trial support, safety checking, and simple communication with doctors and customers. It makes the work of big pharma companies faster and easier, so they can bring safe and effective medicines to people on time, with its smart technology and strong knowledge of healthcare.

What is Indegene Ltd NSE: INDGN?

Indegene, established in 1998 in Ahmedabad, Gujarat, started by Manish Gupta, Rajesh Nair, Sanjay Parikh, Gaurav Kapoor, and Anand Kiran, the company is now situated in Bengaluru. It does work like clinical research, getting government approvals, checking product safety, sharing medical information, and helping them market their products, which helps medicine and healthcare companies. The company uses simple digital tools, technology, data, and AI to make all this work faster and easier.

Indegene Share Price Target

Indegene Share Price Target 2025

It is a global healthcare technology company that works with medicine, biotech, and medical-device companies to help them create new medicines and bring them to the market without problems. The company uses simple digital tools, strong data systems, and modern technology like Artificial Intelligence to make difficult work easier. Indegene supports the complete journey of a medicine from early research to testing in clinical trials and finally launching it for patients. In 2025, its share price target would be ₹681, as per stock market analysts.

According to stock market analysts, its share price would be between ₹472 to ₹681 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	472	681

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	583	681
February	499	640
March	499	598
April	505	587
May	529	622
June	564	632
July	534	586
August	539	593
September	536	596
October	531	587
November	502	544
December	472	576

Indegene Share Price Target 2026

It first started in Ahmedabad, but now its main office is in Bengaluru, Karnataka, which is one of India’s biggest technology cities. From Bengaluru, the company handles work in many countries across North America, Europe, and Asia. It has global delivery centres that work day and night to help clients in different time zones. Since healthcare rules and needs change from country to country, Indegene’s worldwide offices help it understand each place better. In 2026, its share price target would be ₹886, as per stock market analysts.

According to stock market analysts, its share price would be between ₹551 to ₹886 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	551	886

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	551	632
February	561	645
March	578	675
April	587	689
May	610	700
June	621	715
July	630	735
August	647	754
September	652	768
October	667	788
November	725	835
December	758	886

Share Price Target 2027

It mainly works with companies in the life sciences industry, which includes pharmaceutical companies, biotechnology firms, and medical-device makers. These companies face strict rules, long approval processes, and a lot of paperwork. It helps them by giving digital tools, scientific knowledge, and smart technology that make their work simpler. Because the company works only in life sciences, it understands the industry very well and gives highly specialised support. In 2027, its share price target would be ₹1076, as per stock market analysts.

According to stock market analysts, its share price would be between ₹847 to ₹1076 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	847	1076

Share Price Target 2028

The company helps manage trial data, handle patient information, prepare research documents, and make sure that all rules are followed properly. It also uses digital tools to make clinical trials work faster and reduce errors. Indegene helps with choosing patients, checking trial progress, and studying data. Because clinical trials need high accuracy and safety, they help reduce delays and increase the chances of getting approval for new medicines. In 2028, its share price target would be ₹1252, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1041 to ₹1252 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	1041	1252

Share Price Target 2029

It helps healthcare companies promote their products using digital tools. This includes creating online advertisements, making brand content, managing communication with doctors, and studying how customers react to marketing. The company also helps automate marketing tasks, so work becomes faster and easier. Using digital data helps companies understand what doctors and patients want. This helps them share the right information at the right time. In 2029, its share price target would be ₹1410, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1200 to ₹1410 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	1200	1410

Indegene share price Target 2030

Today, healthcare companies need to talk to doctors and patients using many channels like email, apps, websites, videos, webinars, and phone calls. This company provides quick services that help companies communicate in a smooth and organised way across all these platforms. It creates systems that keep the message clear, consistent, and easy to understand everywhere. It also studies how different people prefer to receive information. In 2030, its share price target would be ₹1642, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1374 to ₹1642 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	1374	1642

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1374	1480
February	1390	1497
March	1405	1510
April	1424	1524
May	1435	1535
June	1457	1547
July	1475	1557
August	1490	1575
September	1500	1586
October	1511	1598
November	1520	1624
December	1531	1642

Share Price Target 2040

Artificial Intelligence is one of its strongest areas. The company uses AI to study large amounts of medical data, create content faster, check safety alerts, and organise information quickly. AI helps reduce mistakes, save time, and support better decisions. It uses AI in areas like clinical research, rules and regulations, medical writing, and digital marketing. In 2040, its share price target would be ₹2500, as per stock market analysts.

According to stock market analysts, its share price would be between ₹2182 to ₹2500 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	2182	2500

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	2182	2290
February	2200	2321
March	2210	2342
April	2234	2358
May	2240	2374
June	2257	2390
July	2268	2414
August	2278	2432
September	2290	2445
October	2312	2465
November	2325	2478
December	2377	2500

Share Price Target 2050

It works with many of the world’s biggest pharmaceutical and biotech companies, including several top 20 global pharma firms. These long-term partnerships show that big companies trust Indegene to deliver high-quality, reliable, and large-scale services. The company supports its clients in many different areas such as research, safety checks, medical writing, and marketing. Since large healthcare companies have very heavy workloads, they depend on Indegene to handle complicated tasks efficiently. In 2050, its share price target would be ₹3487, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3161 to ₹3487 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	3161	3487

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3161	3280
February	3187	3299
March	3200	3321
April	3224	3342
May	3238	3352
June	3247	3367
July	3265	3378
August	3287	3390
September	3310	3421
October	3341	3434
November	3358	3454
December	3360	3487

Should I buy Indegene stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	472	681
2026	551	886
2027	847	1076
2028	1041	1252
2029	1200	1410
2030	1374	1642
2040	2182	2500
2050	3161	3487

It could be a good long-term buy because the company’s sales and profits are growing, and it is expanding into many countries. Many experts also believe it can do well in the future. But the stock can go up and down sometimes because costs are rising and big investors keep buying and selling. So, it is better for people who can handle some risk and are ready to hold the stock for a few years, not for someone who wants very safe and steady returns.

Indegene earnings results

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	553	643	966	1,665	2,306	2,590	2,839	3,041
Expenses +	511	499	736	1,378	1,910	2,084	2,292	2,466
Operating Profit	42	144	230	287	396	505	548	575
OPM %	8%	22%	24%	17%	17%	20%	19%	19%
Other Income +	7	-102	-3	-21	58	79	94	105
Interest	6	9	7	6	31	49	22	14
Depreciation	17	19	26	33	60	76	80	86
Profit before tax	26	14	195	226	363	459	539	581
Tax %	45%	191%	23%	28%	27%	27%	25%
Net Profit +	14	-12	149	163	266	337	407	446
EPS in Rs	89.98	-40.20	951.96	937.73	11.99	15.14	16.95	18.58
Dividend Payout %	0%	0%	0%	0%	0%	0%	12%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
28.59	4.87	0.38%	40.20	5.96	0.65%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Indegene Ltd	31.34	4.87	0.38%
Kfin Technologies Ltd	53.17	12.56	0.73%
RITES Ltd	27.97	3.92	3.37%
SIS Ltd	391.19	1.92	—

Is Indegene stock good to buy? (bull case & bear case)

Bull Case:

• In Q2 FY2025-26, it generated 17.1% more revenue than last year and earned a net profit of ₹102.1 crore, indicating the company is growing well.
• For FY2024-25, its sales grew by about 9.6% and net profit grew by 20.8%, meaning the company is improving its earnings every year.
• It has very low debt, and its strong numbers, like high ROE and ROCE, make it a safe and strong company in the healthcare-tech space.
• The company is opening new offices in the US, Europe, and India, which helps it get more big pharma clients and supports long-term growth.
• Some experts say the stock may go up by around 14–15%, which shows that the market has a positive view about the company.

Bear Case:

• The latest results showed that margins went down, meaning costs increased and profit per rupee of revenue became lower, which is not good if it continues.
• Large investors recently sold shares worth over ₹1,400 crore, which made the stock price unstable and created short-term pressure.
• More than 70% of Indegene’s business comes from outside India, so global problems like slow economies, currency changes, or new rules can hurt its growth and profit.

Conclusion

It is a fast-growing healthcare technology company that uses digital tools, AI, and data to help pharma companies make and launch new medicines more smoothly. The company is growing well, has very low debt, and works with many global clients, which is good for its future. But the stock can move up and down because profits have become a bit weaker, some big investors have sold shares, and the business depends a lot on foreign markets. So, it is a good choice for long-term investors who can handle some risk, but not the best for people who want very safe and steady growth.

FAQs